Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. 2cureX AB (publ)
  6. News
  7. Summary
    2CUREX   SE0010468124

2CUREX AB (PUBL)

(2CUREX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

2cureX : successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant.

10/15/2021 | 02:45am EST

2cureX AB (Publ.) announced today that the EU has approved the final status report showing that the MicroCaT project (H2020 no. 777718) met its final objectives by clinically validating IndiTreat® for metastatic colorectal cancer (mCRC) in an interventional clinical trial and make 2cureX’s first product ready for commercialization in Europe.

In February 2018 2cureX started MicroCaT, a project fully funded by the highly prestigious Horizon 2020 SME- Instrument Program of the EU. The success rate for obtaining such grant was 2,8% and entitled 2cureX to receive a maximum of 3,0 MEUR. The EU has now acknowledged that all milestones and deliverables of the project have been reached, and 2cureX has therefore received the final outstanding payment (448.000 EUR) of the 3,0 MEUR grant. 2cureX A/S in Copenhagen with its subsidiary, 2cureX GmbH in Hamburg were the sole beneficiaries in the MicroCaT project. Close collaboration with very important partners including the University hospitals in Vejle (Denmark), Queen Elizabeth Hospital Birmingham (UK) and University Medical Center Hamburg-Eppendorf (Germany) have been key to the success of the project. The SME-Instrument grant is a non-diluting grant that required no co-financing by 2cureX or its subcontractors.

Ole Thastrup, CSO & Founder, 2cureX says “receiving the Grant was a game changing success for 2cureX. It enables us to accelerate our colorectal cancer program and to finalize the clinical validation within the projected timeframe. The grant allowed us to execute on our ambitious plans for conducting the first prospective interventional clinical trial where a 3D microtumor test is guiding treatment of cancer patients, and to use those results to support the market launch of the IndiTreat® mCRC test.” Ole Thastrup continues “Not only did we succeed in preparing the market introduction of our first IndiTreat® product, the MicroCat project did also allow us to establish important partnerships and pave the way for novel IndiTreat® products.”

Jürgen Kupper, CPO and Managing Director of 2cureX GmbH commented “It has been a pleasure to work together with the MicroCaT project team in Brussels – throughout the project the team was very supportive, flexible, pragmatic and efficient. The SME Instrument program is meant to operate according to the needs of the SMEs with a clear purpose of getting innovative ideas and products ready for introduction into the European and global markets. The EU grant has not only allowed us to accelerate the development of the IndiTreat® mCRC product but represented an important support in establishing a new category of precision oncology products.”

© Modular Finance, source Nordic Press Releases

All news about 2CUREX AB (PUBL)
11/252cureX AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
CI
11/242cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth..
AQ
11/242cureX AB Appoints Andrew Beggs to Its Clinical Advisory Board
CI
10/152CUREX : successfully completed the EU-project MicroCaT and received the final financial t..
AQ
10/152curex Successfully Completes the EU-project MicroCaT
CI
10/122CUREX : provides commercial goals for 2022 at Live Strategy Update on the 12th of October..
AQ
10/082CUREX : provides a Live Strategy Update on the company's product portfolio and commercial..
AQ
10/052cureX Signs Distribution Agreement with Labormed in Slovenia
CI
09/282cureX Signs Distribution Agreement with Werfen to Distribute 2cureX Products in Spain
CI
08/262CUREX : Interim Report for the first half-year
PU
More news
Financials
Sales 2021 4,00 M 0,44 M 0,44 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 252 M 27,9 M 27,8 M
Capi. / Sales 2021 63,0x
Capi. / Sales 2022 11,5x
Nbr of Employees 13
Free-Float 62,6%
Chart 2CUREX AB (PUBL)
Duration : Period :
2cureX AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 14,64 
Average target price
Spread / Average Target -
Managers and Directors
Fernando Andreu Chief Executive Officer
Kenneth Graabek Johansen Chief Financial Officer
Povl-AndrÚ Bang Bendz Chairman
Ole Thastrup Director, Deputy CEO & Chief Scientific Officer
Henrik Harling Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
2CUREX AB (PUBL)-11.54%28
EXACT SCIENCES CORPORATION-35.56%14 711
GUARDANT HEALTH, INC.-18.44%10 686
BGI GENOMICS CO., LTD.-28.14%6 119
INVITAE CORPORATION-59.34%3 848
ADAPTIVE BIOTECHNOLOGIES CORPORATION-55.88%3 682